Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13377169 | 0.98 | MEN1 (0.43) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL13377167 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL13377083 | 0.76 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL13377049 | 0.74 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL13377203 | 0.74 | — | — | |
| SCHEMBL13377200 | 0.74 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL13377236 | 0.73 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL13377177 | 0.73 | — | — | |
| SCHEMBL13377174 | 0.72 | KMT2A (0.33) | KMT2A | |
| SCHEMBL13377189 | 0.72 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099561-A1 | HETEROBICYCLIC ALKYLTHIO-BRIDGED ISOXAZOLINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099561-A1 | HETEROBICYCLIC ALKYLTHIO-BRIDGED ISOXAZOLINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099561-A1 | HETEROBICYCLIC ALKYLTHIO-BRIDGED ISOXAZOLINES | UQCRB, CCNB3, CCNB1 | SMN1; SMN2 4756/4885ALDH1A1 3070/4885MEN1 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.